BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Liver cancer (HCC) clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for hepatocellular carcinoma: 218 (150 sponsors; 21 newly posted in the last 180 days, 10 stopped in the last 180 days; 7 new-entrant sponsors). Momentum score 7.8, rank 82 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 3, Phase 1 49, Phase 2 86, Phase 3 36, Phase 4 1, N/A 43.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
AstraZeneca AZN17NA 5, P2 5, P3 6, P1 121
Hoffmann-La Roche4P3 3, NA 101
Akeso6P2 4, P3 202
Exelixis EXEL4P3 2, P1 211
Suzhou Suncadia Biopharmaceuticals Co., Ltd.4P3 2, P1 1, P2 120
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2P3 201
Jiangsu HengRui Medicine Co., Ltd.2P3 200
AbbVie ABBV5P3 1, P1 3, P2 101
Shanghai Henlius Biotech4P2 2, P1 1, P3 102
BeOne Medicines ONC3P2 2, P3 121
Bristol-Myers Squibb BMY3P2 1, NA 1, P3 110
Changchun GeneScience Pharmaceutical Co., Ltd.2NA 1, P3 100
Suzhou Zelgen Biopharmaceuticals Co.,Ltd2P2 1, P3 111
Can-Fite BioPharma CANF1P3 100
Chengdu New Radiomedicine Technology Co. LTD.1P3 100
CStone Pharmaceuticals1P3 100
Guangzhou Virotech Pharmaceutical Co., Ltd.1P3 100
InnoBM Pharmaceuticals Co., Ltd.1P3 100
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.1P3 100
Nanjing Sanhome Pharmaceutical, Co., Ltd.1P3 100
Polaris Group PII1P3 100
Qilu Pharmaceutical Co., Ltd.1P3 100
Tempest Therapeutics TPST1P3 100
Zhejiang Raygene Pharmaceuticals Co., Ltd1P3 100
Boston Scientific Corporation BSX3NA 2, P2 110

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P2AkesoNCT06984718 A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCCHCC; Hepatocellular Carcinomanot yet recruiting120
2026-11-30 est.P2AstraZeneca AZNNCT07081633 Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaHepatocellular Carcinomaactive not recruiting114
2026-12 est.P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04344158 A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular CarcinomaAdvanced Hepatocellular Carcinoma (HCC)active not recruiting648
2026-12 est.P1/P23D Medicines (Sichuan) Co., Ltd.NCT05024214 Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsSolid Tumors; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Hepatocellular Carcinomarecruiting170
2026-12 est.P2Lion TCR Pte. Ltd.NCT05195294 Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCCHepatocellular Carcinoma; Liver Cancer, Adult; Liver Cell Carcinomanot yet recruiting55
2026-12 est.P1/P2OriCell Therapeutics Co., Ltd.NCT05652920 Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCCHepatocellular Carcinomarecruiting105
2026-12 est.P2Zhejiang Haichang Biotech Co., Ltd.NCT06309485 Phase 2 Study of WGI-0301 for Advanced HCCAdvanced Hepatocellular Carcinoma (HCC)recruiting60
2026-12-30 est.P2Teclison Ltd.NCT03259867 Combination of TATE and PD-1 Inhibitor in Liver CancerHepatocellular Carcinoma; Gastric Cancerrecruiting54
2026-12-31 est.P2TaiRx, Inc.NCT05257590 CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular CarcinomaHepatocellular Carcinoma; Advanced Cancerrecruiting95
2027-01 est.P2/P3AbbVie ABBVNCT06109272 A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as aHepatocellular Carcinomaactive not recruiting89
2027-01-01 est.P1/P2Second Life TherapeuticsNCT07341737 SL-28 for Advanced Solid TumoursHead & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cancerecruiting60
2027-02-10 est.P2Shanghai Henlius BiotechNCT06349980 A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally AdvanCarcinoma, Hepatocellularrecruiting117

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-01 est.P2/P3Mirror Biologics, Inc.NCT05033522 Immunotherapy for Advanced Liver CancerHepatocellular Carcinomasuspended150
2026-11 est.P2AbbVie ABBVNCT05822752 Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab Hepatocellular Carcinomaactive not recruiting130
2026-10-31 est.P2Shanghai Henlius BiotechNCT06742892 A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard TherapyCarcinoma, Hepatocellularrecruiting90
2026-10-27 est.P2AstraZeneca AZNNCT05775159 Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerHepatocellular Carcinoma; Biliary Tract Canceractive not recruiting294
2026-10-14 est.P3Hoffmann-La RocheNCT04770896 A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BUnresectable Hepatocellular Carcinomaactive not recruiting557
2026-10-13 est.P1/P2GlaxoSmithKlineNCT06521567 A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With CancerMelanoma; Hodgkin Lymphoma; High and Low Grade Glioma; Glioblastoma Multiforme (GBM); Diffuse Intrinactive not recruiting83
2026-10 est.P3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06618664 A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Advanced Hepatocellular Carcinomarecruiting590
2026-10 est.P1/P2Biotheus Inc.NCT06584071 A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCCHCC; Liver Cancernot yet recruiting140
2026-09-30 est.P3AstraZeneca AZNNCT05557838 Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCCHepatocellular Carcinomaactive not recruiting214
2026-09 est.P2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06558227 Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular CarcinomaHepatocellular Carcinomaunknown90
2026-08-14P1/P2TCM Biotech International Corp.NCT03812874 A Study of PTX-9908 Injection for Non-resectable HCC With TACECarcinoma, Hepatocellularwithdrawn
2026-08 est.P2Tasly Biopharmaceuticals Co., Ltd.NCT06724263 A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid TumorsRecurrent Platinum-resistant Epithelial Ovarian Cancer; Triple Negative Breast Cancer (TNBC); Cervicnot yet recruiting120
2026-07-31 est.P3Jiangsu HengRui Medicine Co., Ltd.NCT04639180 A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence AfteHepatocellular Carcinoma (HCC)active not recruiting687
2026-07-30 est.P3Jiangsu HengRui Medicine Co., Ltd.NCT05320692 A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular CarcinomaHepatocellular Carcinomaactive not recruiting423
2026-07-09P3Bristol-Myers Squibb BMYNCT04039607 A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaHepatocellular Carcinomacompleted732
2026-06-30P2AstraZeneca AZNNCT06040099 A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Hepatocellular Carcinoma (HCC)active not recruiting58
2026-06-30 est.P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT05444088 Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular CarcinomaAdvanced Hepatocellular Carcinomaunknown129
2026-06-15P1/P2T-ACE Medical Co., LtdNCT05435014 T-ACE Oil by TAE/TACE in Patients With Hepatocellular CarcinomaHepatocellular Carcinomaterminated2
2026-06 est.P1/P2AkesoNCT06530251 A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)Hepatocellular Carcinomarecruiting280
2026-05-27P3Bristol-Myers Squibb BMYNCT03383458 A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or AblationHepatocellular Carcinoma; Liver Canceractive not recruiting545

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "hepatocellular carcinoma"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.